Table I.
Viable colony-forming units after continuous treatment with antibiotic fractions, and development of rifampicin-resistant CFUs.
| Antibiotic fractions from CaS/HA-antibiotics pellets | Bacteria tested, and total CFUs before treatment | Mean remaining viable CFUs (range) | Mean rifampicin-resistant CFUs (range) |
|---|---|---|---|
| CaS/HA-VAN CaS/HA-GEN CaS/HA-RIF CaS/HA-VAN+RIF CaS/HA-GEN+RIF |
S. aureus
ATCC 25923, 6.5 × 107 |
5.9 × 107 (5.6 × 107 to 6.5 × 107) 2.4 × 107 (1.4 × 107 to 3.7 × 107) 1.1 × 107 (0 to 4.5 × 107) 0 0 |
0 0 1.8 × 105 (0 to 7.5 × 105) 0 0 |
| CaS/HA-VAN CaS/HA-GEN CaS/HA-RIF CaS/HA-VAN+RIF CaS/HA-GEN+RIF |
S. aureus
clinical strain P-3, 2.8 × 108 |
1.73 × 108 (1.4 × 108 to 1.92 × 108) 2.54 × 108 (2.2 × 108 to 3.1 × 108) 1.05 × 108 (2.5 × 102 to 2.8 × 108) 0 0 |
0 0 9.2 × 107 (0 to 1.9 × 108) 0 0 |
CaS/HA, calcium sulphate/hydroxyapatite; CFU, colony-forming unit; GEN, gentamicin; RIF, rifampicin; VAN, vancomycin.